Hormones and hemodynamics in heart failure.
暂无分享,去创建一个
[1] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[2] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[3] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[4] W. Abraham,et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.
[5] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[6] R. Schrier,et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.
[7] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[8] Y. Sugishita,et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.
[9] A. Luchner,et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. , 1996, Kidney international.
[10] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[11] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[12] W. Abraham,et al. Reversal of atrial natriuretic peptide resistance by increasing distal tubular sodium delivery in patients with decompensated cirrhosis , 1995, Hepatology.
[13] S. Nielsen,et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] T. Saruta,et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. , 1994, The American journal of physiology.
[15] P. Boekstegers,et al. REPEATED ADMINISTRATION OF A F(ab′)2 FRAGMENT OF AN ANTI‐TUMOR NECROSIS FACTOR α MONOCLONAL ANTIBODY IN PATIENTS WITH SEVERE SEPSIS: EFFECTS ON THE CARDIOVASCULAR SYSTEM AND CYTOKINE LEVELS , 1994, Shock.
[16] S. Moncada,et al. The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.
[17] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[18] C. Barberis,et al. Cloning of the Human Type‐2 Vasopressin Receptor Gene , 1993, Annals of the New York Academy of Sciences.
[19] R. Ardaillou,et al. Glomerular effects of angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[20] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[21] Schrier Rw. A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992. , 1992 .
[22] K Rakusan,et al. Morphometry of Human Coronary Capillaries During Normal Growth and the Effect of Age in Left Ventricular Pressure‐Overload Hypertrophy , 1992, Circulation.
[23] B. Groves,et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. , 1992, Journal of the American Society of Nephrology : JASN.
[24] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[25] K. Pennert,et al. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.
[26] R. Schrier,et al. Pathogenesis of ascites formation : mechanism of impaired aldosterone escape in cirrhosis , 1991 .
[27] W. Abraham,et al. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. , 1991, American journal of nephrology.
[28] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[29] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[30] R. Schrier. Body fluid volume regulation in health and disease: a unifying hypothesis. , 1990, Annals of internal medicine.
[31] H. Drexler,et al. Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. , 1990, Circulation research.
[32] L. Navar,et al. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. , 1989, The American journal of physiology.
[33] W. Suki. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. , 1989, Archives of internal medicine.
[34] R. Schrier,et al. Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. , 1989, Kidney international.
[35] W. Oelkers,et al. Effects of Incremental Infusions of Atrial Natriuretic Factor on Aldosterone, Renin, and Blood Pressure in Humans , 1988, Hypertension.
[36] G. Dibona,et al. Neural control of renal function in edema-forming states. , 1988, The American journal of physiology.
[37] R. Schrier. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2) , 1988, The New England journal of medicine.
[38] H. Itoh,et al. Atrial natriuretic polypeptide (ANP) in human ventricle. Increased gene expression of ANP in dilated cardiomyopathy. , 1987, Biochemical and biophysical research communications.
[39] Andrew,et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.
[40] B. Brenner,et al. Renal and Systemic Hemodynamic Effects of Synthetic Atrial Natriuretic Peptide in the Anesthetized Rat , 1986, Circulation research.
[41] K. Okada,et al. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. , 1986, Kidney international.
[42] M. Packer,et al. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.
[43] C. Johnston,et al. Role of Vasopressin in Experimental Congestive Cardiac Failure , 1986, Journal of cardiovascular pharmacology.
[44] B. Rolls,et al. Angiotensin II-induced thirst and vasopressin release in man. , 1985, Clinical science.
[45] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[46] J. Cohn,et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.
[47] S. Satoh,et al. Effects of renal nerve stimulation, norepinephrine and angiotensin II on renal blood flow in relation to release of PG-like substances in anesthetized dogs. , 1981, Archives internationales de pharmacodynamie et de therapie.
[48] T. Berl,et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.
[49] R. Venuto,et al. Acute oliguric renal failure induced by indomethacin: possible mechanism. , 1979, Annals of internal medicine.
[50] T. Berl,et al. Osmotic and nonosmotic control of vasopressin release. , 1979, The American journal of physiology.
[51] C. W. Gottschalk,et al. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. , 1976, The Journal of clinical investigation.
[52] B. Brenner,et al. Effects of Norepinephrine and Angiotensin II on the Determinants of Glomerular Ultrafiltration and Proximal Tubule Fluid Reabsorption in the Rat , 1975, Circulation research.
[53] T. Berl,et al. Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. , 1973, The Journal of clinical investigation.
[54] J. P. Gilmore,et al. Contribution of Baroreceptors to the Control of Renal Function , 1964, Circulation research.
[55] J. Henry,et al. The effect of negative pressure breathing on urine flow. , 1954, The Journal of clinical investigation.